Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Change in Account Payables (2019 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Change in Account Payables for 3 consecutive years, with -$694000.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Change in Account Payables fell 51.2% year-over-year to -$694000.0, compared with a TTM value of $1.6 million through Dec 2021, up 46.77%, and an annual FY2024 reading of $1.7 million, up 181.91% over the prior year.
  • Change in Account Payables was -$694000.0 for Q4 2021 at Black Diamond Therapeutics, down from $628000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.9 million in Q3 2020 and bottomed at -$3.8 million in Q2 2020.
  • Average Change in Account Payables over 3 years is $341000.0, with a median of $275000.0 recorded in 2019.
  • Peak annual rise in Change in Account Payables hit 4533.33% in 2020, while the deepest fall reached 1258.33% in 2020.
  • Year by year, Change in Account Payables stood at $958000.0 in 2019, then crashed by 147.91% to -$459000.0 in 2020, then crashed by 51.2% to -$694000.0 in 2021.
  • Business Quant data shows Change in Account Payables for BDTX at -$694000.0 in Q4 2021, $628000.0 in Q3 2021, and -$356000.0 in Q2 2021.